PRECLINICAL ANTITUMOR ACTIVITY OF THIARABINE IN HUMAN LEUKEMIA AND LYMPHOMA XENOGRAFT MODELS

被引：3
|
作者：
Waud, William R. [1 ]
Gilbert, Karen S. [1 ]
Secrist, John A., III [1 ]
机构：
[1] So Res Inst, Canc Therapeut & Immunol Dept, Birmingham, AL 35255 USA
来源：
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2012年 / 31卷 / 09期
关键词：
Thiarabine; leukemia; lymphoma; ara-C; clofarabine; fludarabine monophosphate; cladribine; gemcitabine; 4'-THIO-BETA-D-ARABINOFURANOSYLCYTOSINE 4'-THIO-ARA-C; GEMCITABINE; P388;
D O I：
10.1080/15257770.2012.710768
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Thiarabine was evaluated for antitumor activity in seven human leukemia, lymphoma, and myeloma xenograft models to explore the activity in hematological malignancies. Thiarabine was active against all of the human leukemia and lymphoma lines tested, being curative against HL-60 leukemia and AS283 lymphoma and effecting tumor regressions in CCRF-CEM, MOLT-4, and K-562 leukemia and RL lymphoma models, but did not exhibit any appreciable activity against RPMI-8226 myeloma. For the leukemia/lymphoma models, thiarabine was more efficacious than ara-C/palmO-ara-C (four models), clofarabine (three models), fludarabine monophosphate (five models), cladribine (four models), and gemcitabine (six models). Thiarabine warrants future clinical trials with leukemias/lymphomas.
引用
收藏
页码：647 / 660
页数：14
相关论文
共 50 条
  • [21] Antitumor activity of Endostar combined with radiation against human nasopharyngeal carcinoma in mouse xenograft models
    Zhou, Juying
    Wang, Lili
    Xu, Xiaoting
    Tu, Yu
    Qin, Songbing
    Yin, Yuzhen
    ONCOLOGY LETTERS, 2012, 4 (05) : 976 - 980
  • [22] Antitumor Activity of MLN9708, a Second-Generation Proteasome Inhibitor, in Preclinical Models of Lymphoma
    Donelan, Jill
    Bannerman, Bret
    Bano, Kristen
    Babcock, Trisha
    Hales, Paul
    Stringer, Bradley
    Burke, Kristine
    Danaee, Hadi
    Faron-Yowe, Laura
    Koenig, Erik
    Lichter, David
    Kupperman, Erik
    BLOOD, 2009, 114 (22) : 1434 - 1435
  • [23] Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
    Al-Katib, Ayad M.
    Aboukameel, Amro
    Mohammad, Ramzi
    Bissery, Marie-Christine
    Zuany-Amorim, Claudia
    CLINICAL CANCER RESEARCH, 2009, 15 (12) : 4038 - 4045
  • [24] Lenvatinib in combination with everolimus demonstrated enhanced antiangiogenesis and antitumor activity in human RCC xenograft models
    Adachi, Yusuke
    Matsuki, Masahiro
    Yamaguchi, Atsumi
    Ozawa, Yoichi
    Okamoto, Kiyochi
    Mitsuhashi, Kaoru
    Kimura, Takayuki
    Hoshi, Taisuke
    Tohyama, Osamu
    Tai, Kenji
    Ogo, Makoto
    Funahashi, Yasuhiro
    Matsui, Junji
    CANCER RESEARCH, 2016, 76
  • [25] Preclinical Anti-Tumor Activity of Hexabody-CD38 in Patient-Derived B Cell Lymphoma and Acute Myeloid Leukemia Xenograft Models
    Hiemstra, Ida H.
    Janmaat, Maarten L.
    Boross, Peter
    Van den Brakel, Jeroen
    ten Hagen, Wessel
    van Dooremalen, Sanne
    Bosgra, Sieto
    De Goeij, Bart E. C. G.
    Andringa, Grietje
    Kil, Laurens
    Sasser, A. Kate
    Ahmadi, Tahamtan
    Satijn, David
    Breij, Esther C. W.
    BLOOD, 2020, 136
  • [26] Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models
    Matsuzaki, Takeshi
    Takagi, Akimitsu
    Furuta, Tomio
    Ueno, Satoshi
    Kurita, Akinobu
    Nohara, Gou
    Kodaira, Hiroshi
    Sawada, Seigo
    Hashimoto, Shusuke
    ONCOLOGY REPORTS, 2012, 27 (01) : 189 - 197
  • [27] Antitumor activity of a novel small molecule agent PRLX 93936 against human tumor xenograft models
    Robbins, Paul
    Clemens, Chris
    Pierce, Michael
    Peltier, John
    Selliah, Robert
    Venkat, Raj Gopal
    Rebentisch, Matt
    Lai, Shuping
    Becklin, Robert
    Senina, Anna
    O'Mel, Vlad
    Erkkila, Tracy
    Sahasrabudhe, Sudhir R.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3444S - 3444S
  • [28] Src family kinase inhibition demonstrates antitumor activity in vitro and in patientderived xenograft models of human cholangiocarcinoma
    Kuipers, Hendrien
    Tomlinson, Jennifer L.
    Carlson, Danielle M.
    Abdelrahman, Amro M.
    Jessen, Erik
    Sample, Jack W.
    Werneburg, Nathan W.
    Stumpf, Hannah E.
    Truty, Mark J.
    Ilyas, Sumera I.
    Gores, Gregory J.
    Smoot, Rory L.
    CANCER RESEARCH, 2024, 84 (06)
  • [29] Antitumor activity of IHL-305, a novel PEGylated liposome containing irinotecan, in human xenograft models
    Takagi, A.
    Matsuzaki, T.
    Furuta, T.
    Ueno, S.
    Nohara, G.
    Kodaira, H.
    Sawada, S.
    Hashimoto, S.
    EJC SUPPLEMENTS, 2006, 4 (12): : 50 - 50
  • [30] Antitumor efficacy of OSI-930 and the molecular targeted agent erlotinib in preclinical xenograft models
    Rosenfeld-Franklin, M.
    Silva, S.
    Pirritt, C.
    Cooke, A.
    Bittner, M.
    Wolf, J.
    Epstein, D.
    Wild, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345